Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.


Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
04 2019
Historique:
received: 30 10 2018
revised: 14 01 2019
accepted: 22 01 2019
pubmed: 3 2 2019
medline: 14 5 2019
entrez: 3 2 2019
Statut: ppublish

Résumé

Gastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix. As shown in the original Japanese group description, in recent studies, GAS represents a more aggressive disease than the usual-type endocervical adenocarcinoma (UEA). Detailed clinicopathological features of this variant remain to be elucidated in a larger series of patients. Patients were enrolled by the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group after receiving the approval of each Institutional Review Board. The study population comprised of women with stage I to II endocervical adenocarcinomas who underwent surgery between 2000 and 2009. Representative slides were evaluated by central pathological review (CPR), categorized into either GAS or UEA, and correlated with clinicopathological features and outcome. Among the 393 enrolled patients with endocervical adenocarcinoma, 328 patients met the criteria for CPR and the study eligibility criteria and were included in further analysis. A total of 95 of the 328 tumors were classified as GAS. Compared with UEA, GAS was more significantly associated with bulky mass, deep stromal invasion, lymphovascular space invasion, parametrial invasion, ovarian metastasis, positive ascitic fluid cytology, pelvic lymph node metastasis, and pathological (p) T stage but was not related to the degree of histological differentiation. Disease-free survival (P < 0.0001) and overall survival (P < 0.0001) were poorer in patients with GAS than in those with UEA. GAS showed aggressive behavior with ominous histopathological predictors as well as decreased survival. GAS is therefore considered a distinct entity that should be distinguished from UEA. UMIN Clinical Trials Registry: UMIN000007987.

Identifiants

pubmed: 30709650
pii: S0090-8258(19)30063-0
doi: 10.1016/j.ygyno.2019.01.022
pii:
doi:

Banques de données

UMIN-CTR
['UMIN000007987']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-19

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Auteurs

Shin Nishio (S)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.

Yoshiki Mikami (Y)

Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.

Hideki Tokunaga (H)

Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Nobuo Yaegashi (N)

Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Toyomi Satoh (T)

Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Motoaki Saito (M)

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

Aikou Okamoto (A)

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

Takahiro Kasamatsu (T)

Department of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Tsutomu Miyamoto (T)

Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.

Tanri Shiozawa (T)

Department of Obstetrics and Gynecology, Shinshu University School of Medicine, Matsumoto, Japan.

Yumiko Yoshioka (Y)

Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Masaki Mandai (M)

Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Atsumi Kojima (A)

Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

Kazuhiro Takehara (K)

Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.

Eisuke Kaneki (E)

Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hiroaki Kobayashi (H)

Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Tsunehisa Kaku (T)

Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Kimio Ushijima (K)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

Toshiharu Kamura (T)

Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH